They missed the first big run but Rachel Folder explains why that doesn’t mean the opportunity is lost.

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market.

The RBA’s proposed surcharge ban and fee caps may reshape payments, but Visa and Mastercard are already positioned for the shift.

Explore U.S. economic trends: growth uncertainty and rising inflation risks.

Greg Sharenow, managing director and portfolio manager, charts the continued resilience of commodities and their low correlation with stocks and bonds amid recent...

Australian bonds experienced a resurgence, posting their best financial year since 2018/19. Some managers returned close to 10%.

In a market full of flashy tech and speculative growth stories, here's a refreshingly grounded stock to watch.

Five global equity funds delivered returns of more than 37% despite the FY25 turmoil.

While markets chase the AI hype, medtech quietly trades at decade-lows. Here’s why that’s an opportunity for long-term patient investors.

By learning to avoid mistakes you can improve your returns as much by learning what qualities to look for in a business.

Rational investors have abandoned CBA, resulting in a share price that gets 'pushed around' by passive and momentum flows.

Forget AI stocks. It was the old-world store of value and the new-age digital gold that stole the show in FY25.

Alphabet’s real strength isn’t in its parts, it’s in their integration. Break it up, and the signal powering Google ads deteriorates.

In this wire, we crunch the data on the country's top-performing Aussie equities funds for FY25 and examine their positioning.

Bloomberg is talking a once-in-a-generation copper trade. Get ready to be sold to! Traders want you to take the other side of this trade.

Wide valuation gaps between the popular and unpopular offer extremely good prospects for those prepared to avoid the crowds.

The passage of the so-called “Big Beautiful Bill” will, by itself, boost growth over the medium term. However, offsetting the extent of any boost will be ever-changing...

With the AT1 hybrid market being phased out, investors will be looking for solutions. VanEck has a handful of ETFs that could fill the void.